By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Dainippon Sumitomo Pharma Co., Ltd. 

2-6-8 Doshomachi, Chuo-ku

Osaka    541-0045  Japan
Phone: 06-6203-5321 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Dainippon Sumitomo Pharma Co., Ltd. Halts Key Phase 3 Global Colorectal Carcinoma Monotherapy Trial 5/27/2014 7:31:54 AM
Edison Pharmaceuticals, Inc. Announces Initiation Of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co., Ltd. In Japan 3/10/2014 12:29:22 PM
Edison Pharmaceuticals, Inc., Dainippon Sumitomo Pharma Co., Ltd. Ink "Biological Energy" Pact Worth $4.3 Billion 1/31/2014 6:48:05 AM
Retina Institute Japan and Dainippon Sumitomo Pharma Co., Ltd. Form a Capital Alliance Towards the Development of Nobel Prize Winning iPS Cell Technology 3/29/2013 9:07:02 AM
Edison Pharmaceuticals, Inc. Signs Licensing Agreement With Dainippon Sumitomo Pharma Co., Ltd. for Up to $545 Million 3/28/2013 7:35:41 AM
Dainippon Sumitomo Pharma Co., Ltd. Sumitomo Seeks SFDA Approval for Cancer Drug 9/4/2012 10:25:58 AM
Dainippon Sumitomo Pharma Co., Ltd. Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression 5/7/2012 7:34:12 AM
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C’s Life Sciences Practice Represents Boston Biomedical in its Agreement with Dainippon Sumitomo Pharma Co., Ltd. to be Acquired for up to $2.63 Billion 3/5/2012 6:04:27 AM
Dainippon Sumitomo Pharma Co., Ltd. Bags Boston Biomedical for $2.6 Billion 2/29/2012 7:28:33 AM
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells 4/7/2011 8:06:38 AM
1234
//-->